Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited reports on share repurchase activities for the period from February 1, 2022, to February 28, 2022. The report was filed on March 14, 2022, pursuant to the Financial Instruments and Exchange Act of Japan. The company is a foreign private issuer reporting under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing focuses exclusively on capital allocation via share buybacks and does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Repurchase Program Authorization: Approved by the Board of Directors on October 28, 2021, for up to 35,000,000 shares with a total budget of JPY 100,000,000,000.
- Repurchase Period: November 2, 2021, to April 29, 2022.
- Shares Repurchased in February 2022: 7,133,700 shares.
- Total Amount Spent in February 2022: JPY 24,992,756,700.
- Cumulative Shares Repurchased (as of Feb 28, 2022): 22,469,400 shares.
- Cumulative Amount Spent (as of Feb 28, 2022): JPY 74,972,698,800.
- Program Progress: 64.20% of authorized shares and 74.97% of authorized budget utilized.
- Treasury Shares Held (as of Feb 28, 2022): 22,645,558 shares.
- Total Issued Shares: 1,582,252,525 shares.
Material Changes
The filing details specific transaction dates and volumes for February 2022 but does not provide comparative data against the prior month or prior year to assess material changes in repurchase velocity or pricing trends. The filing notes that 89 shares were disposed of in the reporting month (totaling JPY 306,427) upon request by shareholders holding less than one unit.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or risk factors. It is a statutory disclosure of share repurchase execution. The repurchase program is scheduled to conclude on April 29, 2022, unless terminated earlier.
Investor Verification Checklist
- Verify the remaining budget and share count available for repurchase under the October 2021 Board resolution.
- Confirm the average price per share paid during the February 2022 reporting period (approximately JPY 3,503 per share based on total amount and volume).
- Check subsequent filings for the final status of the repurchase program upon its April 29, 2022, expiration.
- Note that treasury share counts exclude shares held by the ESOP trust account and the BIP trust account.